For information on the latest Parkinson’s research please visit the European Parkinson’s Disease Association website.
Horse tranquiliser trial is awarded $750,000 grant for Parkinson’s research
Author: Simge Eva DoganPublished: 26 July 2018
Prep: Cook: Serves:
Researchers at the University of Arizona College of Medicine, Tucson, US, will be trialling ketamine – a recreational drug previously used to medicate people with depression – as a treatment for Parkinson’s.
The research – led by Dr Scott Sherman – is being supported with a three-year grant of $750,000 from the Arizona Biomedical Research Commission.
The initial clinical trial will test the effect of ketamine for treating dyskinesia in 10 patients. In addition, the researchers will carry out a separate rodent study to examine how the drug affects the brain.
Dr Scott Sherman, a neurologist at the University of Arizona College of Medicine, said: “Ketamine has been long overlooked. Now it could prove very useful for Parkinson’s patients.”
For more information on this article click here.
Share this story
Parkinson Italia launches multi-stakeholder White Book research project
Major new study will help create ‘patient wellbeing scale’READ MORE
Cramping more than your style
Register for this free hour-long webinarREAD MORE
Highlights: Cycle Venice to Rome, ItalyREAD MORE